33 articles
Alan F. List
Alan F. List is an American hematologic oncologist whose clinical research established lenalidomide as the standard of care for myelodysplastic syndromes with chromosome 5q deletion.
Anastasios Karadimitris
Anastasios Karadimitris, known as Tassos, is a Greek-trained hematologist and Professor at Imperial College London known for identifying inherited GPI deficiency and developing CAR-iNKT cell immunotherapy.
Angela Dispenzieri
Angela Dispenzieri is a hematologist and professor of medicine at Mayo Clinic in Rochester, Minnesota, on the faculty since 1998 and known for work on multiple myeloma, AL amyloidosis, and POEMS syndrome.
Antonio Palumbo
Antonio Palumbo is an Italian hematologist who led the myeloma unit in Turin and landmark New England Journal of Medicine trials, including the 2014 transplantation trial and the 2016 CASTOR daratumumab trial.
Bart Barlogie
Bart Barlogie is a German-born physician-scientist in hematology who developed Total Therapy for multiple myeloma and founded the Myeloma Institute at the University of Arkansas.
Elliott F. Osserman
Elliott F. Osserman was a physician-scientist in hematology and immunology at Columbia University whose 1959 review reframed multiple myeloma as one pattern of a single plasma-cell disease.
Gareth J. Morgan
Gareth J. Morgan, also published as Gareth Morgan, is a hematologist directing multiple myeloma research at NYU Langone's Perlmutter Cancer Center; he led the Myeloma IX trial.
Giovanni Tonon
Giovanni Tonon is an Italian physician-scientist in hematology and cancer genomics, a full professor and director of the Centre for Omics Sciences at Vita-Salute San Raffaele University in Milan.
Gösta Gahrton
Gösta Gahrton is a Swedish hematologist and professor emeritus at Karolinska Institutet in Stockholm, known for establishing allogeneic stem cell transplantation as a treatment for multiple myeloma.
Guido Tricot
Guido J. Tricot is a Belgian-born hematologist-oncologist and myeloma researcher known for developing Total Therapy, which raised median survival for newly diagnosed patients from 2.5 years to 10 or more.
Heinz Ludwig
Heinz Ludwig (born 1947) is an Austrian hematologist-oncologist who leads the Wilhelminen Cancer Research Institute in Vienna, known for showing in 1990 that erythropoietin corrects myeloma anemia.
Hervé Avet‐Loiseau
Hervé Avet-Loiseau is a French hematologist-oncologist known for the genetics and genomics of multiple myeloma, who led the Myeloma Genomics unit at the Cancer Research Center of Toulouse.
Irene M. Ghobrial
Irene M. Ghobrial is an Egyptian-born American physician-scientist at Dana-Farber Cancer Institute and Harvard Medical School who studies multiple myeloma precursors and led the CAR-PRISM trial treating high-risk smoldering myeloma.
John D. Shaughnessy
John D. Shaughnessy is an American molecular biologist and multiple myeloma researcher who is a professor at the University of Arkansas for Medical Sciences Myeloma Center.
Kenneth C. Anderson (hematologist-oncologist)
Kenneth C. Anderson is an American hematologist-oncologist at Dana-Farber Cancer Institute whose work helped extend multiple myeloma survival from about 3 to over 7 years.
María‐Victoria Mateos
María-Victoria Mateos (María Victoria Mateos Manteca) is a Spanish hematologist and multiple myeloma researcher at Salamanca, known for the ALCYONE trial and bispecific antibody studies.
Mario Boccadoro
Mario Boccadoro (born 1950) is an Italian hematologist and emeritus professor at the University of Turin who led landmark multiple myeloma trials, including a 2006 Lancet study of melphalan, prednisone, and thalidomide.
Meletios Α. Dimopoulos
Meletios A. Dimopoulos is a Greek hematologist and multiple myeloma researcher who led landmark myeloma drug trials and served as Rector of the National and Kapodistrian University of Athens.
Michel Attal
Michel Attal is a French hematologist and professor at Université Paul Sabatier in Toulouse, known for trials establishing transplantation and lenalidomide maintenance as standard myeloma treatment.
Michèle Cavo
Michele Cavo is an Italian hematologist and Full Professor of Hematology at the University of Bologna, where he heads the Seràgnoli Institute of Hematology and researches multiple myeloma.
Morie A. Gertz
Morie A. Gertz is an American hematologist at the Mayo Clinic in Rochester, Minnesota, known for his work on AL amyloidosis and multiple myeloma, including the 2012 revised staging system.
Nikhil C. Munshi
Nikhil C. Munshi is an Indian-born hematologist who directs myeloma research and CAR T-cell therapy at Dana-Farber, and led the 2021 trial of idecabtagene vicleucel for myeloma.
Nizar J. Bahlis
Nizar J. Bahlis is a Canadian hematologist and multiple myeloma researcher at the University of Calgary, where he is an Associate Professor of Medicine, known for leading trials of elranatamab and mezigdomide.
Noopur Raje
Noopur Raje (Noopur S. Raje) is a hematologist-oncologist directing the Center for Multiple Myeloma at Massachusetts General Hospital, known for leading the first-in-human trial of the CAR T-cell therapy idecabtagene vicleucel.
O. Ross McIntyre
O. Ross McIntyre (O. R. McIntyre) is an American hematologist-oncologist and Emeritus Professor of Medicine at Dartmouth, director of Norris Cotton Cancer Center from 1975 to 1992.
Ola Landgren
C. Ola Landgren is a Swedish-trained hematologist-oncologist specializing in multiple myeloma who has led myeloma programs at the NCI, Memorial Sloan Kettering, and the University of Miami.
Philippe Moreau
Philippe Moreau is a French hematologist, University Professor of Clinical Hematology at the University of Nantes, best known as principal investigator of the CASSIOPEIA and MajesTEC-1 multiple myeloma trials.
Pieter Sonneveld
Pieter Sonneveld is a Dutch professor of hematology at Erasmus MC Rotterdam, head of hematology from 2011 to 2017, known for the daratumumab trials CASTOR, CASSIOPEIA, and PERSEUS and for founding the European Myeloma Network.
S. Vincent Rajkumar
S. Vincent Rajkumar, also known as Vincent Rajkumar, is an American hematologist-oncologist at Mayo Clinic in Rochester, Minnesota, known for redefining myeloma diagnosis and leading pivotal myeloma drug trials.
Sagar Lonial
Sagar Lonial is an American hematologic oncologist who chairs hematology and medical oncology at Emory University and leads pivotal multiple myeloma trials, including daratumumab, elotuzumab, and iberdomide.